Radiopharm Theranostics Limited (RADX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Radiopharm Theranostics L...

NASDAQ: RADX · Real-Time Price · USD
6.20
0.14 (2.31%)
At close: Oct 03, 2025, 3:55 PM
6.29
1.45%
After-hours: Oct 03, 2025, 05:41 PM EDT

Radiopharm Theranostics Income Statement

Financials in AUD. Fiscal year is July - June.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Jun 30, 2025 Jun 30, 2024 Jun 30, 2023 Jun 30, 2022
Revenue
3.63M 299.23K 292.36K 8.83K
Cost of Revenue
3.59M n/a n/a n/a
Gross Profit
39.28K 299.23K 292.36K 8.83K
Operating Income
-38.17M -36.62M -34.51M -19.92M
Interest Income
888.2K 50.48K 145.03K n/a
Pretax Income
-38.24M -47.85M -34.57M -30.29M
Net Income
-38.34M -47.95M -34.61M -30.34M
Selling & General & Admin
16.53M 15.22M 13.02M 10.85M
Research & Development
27.52M 17.56M 13.8M 4.12M
Other Expenses
-5.83M 4.14M 7.98M 4.95M
Operating Expenses
38.21M 36.92M 34.8M 19.93M
Interest Expense
65.3K 642.89K 86.09K 9.35M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
41.81M 36.92M 34.8M 19.93M
Income Tax Expense
103.29K 96.36K 38.01K 44.4K
Shares Outstanding (Basic)
6.94M 1.29M 1.02M 1.02M
Shares Outstanding (Diluted)
6.94M 1.29M 1.02M 1.02M
EPS (Basic)
-5.28 -36 -33 -29.76
EPS (Diluted)
-5.28 -36 -33 -29.76
EBITDA
-38.17M -44.08M -31.19M -17.96M
EBIT
-38.17M -47.21M -34.49M -20.94M
Depreciation & Amortization
7.33K 3.13M 3.3M 2.98M